___

• 1. Obesity. Preventing and managing the global epidemic: Report of a WHO consultation. World Health Organ Tech Rep Ser 2000; 894: i-xii, 1-253.
• 2. Onat A, Ceyhan K, Başar Ö, Erer B, Toprak S, Sansoy V. Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels – a prospective and cross- sectional evaluation. Atherosclerosis 2002; 165: 285-92.
• 3. Onat A, Uyarel H, Hergenç G, Karabulut A, Albayrak S, Can G. Determinants and definition of abdominal obesity as related to risk of diabetes, metabolic syndrome and coronary disease in Turkish men: a prospective cohort study. Atherosclerosis 2007; 191: 182-90.
• 4. Onat A, Sarı İ, Hergenç G, Yazıcı M, Can G, Uyarel H et al. Predictors of abdominal obesity and high susceptibility of cardiometabolic risk to its increments among Turkish women: a prospective population-based study. Metabolism 2007; 56: 348-56.
• 5. Hergenc G, Schulte H, Assmann G, von Eckardstein A. Association of obesity markers, insulin, and sex hormones with HDL-cholesterol levels in Turkish and German individuals. Atherosclerosis 1999; 145: 147-156.
• 6. Schwandt P, Geiss HC, Ritter MM, Üblacker C, Parhofer KG, Otto C et al. The Prevention Education Program (PEP). A prospective study of the efficacy of family-oriented lifestyle modification: design and baseline data. J Clin Epidemiol 1999; 52: 791-800.
• 7. Porsch-Oezçürümez M, Bilgin Y, Wollny M, Gediz A, Arat A, Karatay E et al. The Giessen Study Group. Prevalence of risk factors of coronary heart disease in Turks living in Germany. Atherosclerosis 1999; 144: 185-98.
• 8. Onat A. Risk factors and cardiovascular disease in Turkey. Atherosclerosis 2001; 156: 1-10.
• 9. Onat A, Özhan H, Esen AM, Albayrak S, Karabulut A, Can G et al. Prospective epidemiologic evidence of a “protective” effect of smoking on metabolic syndrome and diabetes among Turkish women – without associated overall health benefit. Atherosclerosis 2007; 193: 380-8.
• 10. Onat A, Avcı GŞ, Şenocak M, Örnek E, Gözükara Y. Plasma lipids and their interrelation in Turkish adults. J Epidem Commun Health 1992; 46: 470-476.
• 11. World Health Organisation. Measuring obesity – classification and description of anthropometric data. Report on a WHO consultation on the epidemiology of obesity. Copenhagen: WHO Regional Office for Europe, 1987; [EUR/ICP/NUT 125, 0612v].
• 12. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
• 13. Onat A, Avcı GŞ, Barlan MM, Uyarel H, Uzunlar B, Sansoy V. Measures of abdominal obesity assessed for visceral adiposity and relation to coronary risk. Int J Obes 2004; 28: 1018-25.
• 14. Han TS, Seidell JC, Currall JE, Morrison CE, Deurenberg P, Lean ME. The influences of height and age on waist circumference as an index of adiposity in adults. Int J Obes 1997; 21: 83-9.
• 15. Hsieh SD, Yoshinaga H. Abdominal fat distribution and coronary heart disease risk factors in men – waist-height ratio as a simple and useful predictor. Int J Obes 1995; 19: 585-9.
• 16. Panagiotakos DB, Pitsavos C, Yannakoulia M, Chrysohoou C, Stefanadis C. The implication of obesity and central fat on markers of chronic inflammation: the ATTICA study. Atherosclerosis 2005; 187: 308-15.
• 17. Teran-Garcia M, Després J-P, Couillard C, Tremblay A, Bouchard C. Effects of long-term overfeeding on plasma lipoprotein levels in identical twins. Atherosclerosis 2004; 173: 277-83.
• 18. Mahley RW, Palaoğlu E, Atak Z, Dawson-Pepin J, Langlois AM, Cheung V et al. Turkish Heart Study: lipids, lipoproteins, and apolipoproteins. J Lipid Res 1995; 36: 839-859.
• 19. Hodoglugil U, Tanyolac S, Williamson DW, Huang Y, Mahley RW. Apolipoprotein A-V: a potential modulator of plasma triglyceride levels in Turks. J Lipid Res. 2006; 47: 144-53.
• 20. Onat A, Ayhan E, Hergenç G, Can G, Barlan MM. Smoking inhibits visceral fat accumulation in Turkish females: Relation of visceral fat and body fat mass to atherogenic dyslipidemia, inflammatory markers, insulin resistance and blood pressure. Metabolism 2009; 58: 963-70.
• 21. Onat A, Hergenç G. Reduced asymmetric dimethylarginine (ADMA) levels mediate in the protection from metabolic syndrome by smoking. (Letter) Atherosclerosis 2008; 196: 479-80.
• 22. Onat A, Can G, Hergenç G. Serum C-reactive protein is an independent risk factor predicting cardiometabolic risk. Metabolism 2008; 57: 207-14.
• 23. Xu F, Yin XM, Wang Y. The association between amounts of cigarettes smoked and overweight, central obesity among Chinese adults in Nanjing, China. Asia Pac J Clin Nutr 2007; 16: 240-7.
• 24. Pisinger C, Jorgensen T. Waist circumference and weight following smoking cessation in a general population: the Inter99 study. Prev Med 2007; 44: 290-5.
• 25. Clouse WD, Yamaguchi H, Phillips MR, Hurt RD, Fitzpatrick LA, Moyer TP et al. Effects of transdermal nicotine treatment on structure and function of coronary artery bypass grafts. J Appl Physiol 2000; 89: 1213-23.
• 26. Seidell JC, Perusse L, Després JP, Bouchard C. Waist and hip circumferences have independent and opposite effects on cardiovascular disease risk factors: the Quebec Family Study. Am J Clin Nutr 2001; 74: 315-21.
• 27. Canoy D, Wareham N, Luben R, Welch A, Bingham S, Day N et al.. Serum lipid concentration in relation to anthropometric indices of central and peripheral fat distribution in 20,021 British men and women: Results from the EPIC-Norfolk population-based cohort study. Atherosclerosis 2006; 189: 420- 7.